ShareValue scores for SLGL: Valuation 41, Quality 46, Growth 49, Health 57.

SLGL
NASDAQ

Sol Gel Technologies Ltd

$54.08(+1.35%)

Updated

Loading chart...
Sentiment

Pulse

Rating

Moderate

Trap Risk

P/E to median

Not enough data
Valuation
41
Fair Value

vs US-listed micro-cap Healthcare stocks

Price vs Value
Quality
46
Moderate
Business Strength
Growth
49
Moderate
Revenue & Earnings
Health
57
Moderate
Financial Stability
Price trend
59
Neutral
Separate from the four scores

Company Details

About

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Score Analysis

AI Investment Thesis

Data as of:Nov 20, 2026

By using ShareValue.ai you agree to our Terms and Privacy Policy. Educational platform, not investment advice.